765 results on '"Mack, Philip C."'
Search Results
102. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma
103. Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012
104. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
105. Additional file 8 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
106. Additional file 5 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
107. Additional file 1 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
108. Additional file 7 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
109. Additional file 3 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
110. Additional file 4 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
111. Additional file 2 of A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
112. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy
113. Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2
114. Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study
115. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)
116. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer
117. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
118. KRAS G12C–Mutant Non–Small Cell Lung Cancer
119. Schedule-Dependent Apoptosis in K-ras Mutant Non–Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation
120. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers with Lung Adenocarcinoma
121. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
122. Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non–Small-Cell Lung Cancer: Implications for Therapy
123. Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer
124. Aurora Kinase Inhibitors: A New Class of Targeted Drugs in Cancer
125. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the ‘common arm’ approach
126. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
127. Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity
128. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration
129. Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines
130. Aberrant Regulation of the MRP3 Gene in Non-small Cell Lung Carcinoma
131. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
132. Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial
133. Ethnic difference in lung cancer: an important issue in a globalized society
134. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.
135. Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).
136. SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
137. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases
138. Molecular Biology of Lung Cancer as the Basis for Targeted Therapy
139. Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer
140. Multidrug Resistant Protein-three (MRP3) Gene Regulation by Nrf2 and p53 in Human Bronchial Epithelial and NSCLC: 478
141. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.
142. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC.
143. Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines
144. 2008 Highlights from: The IASLC-ESMO 1st European Lung Cancer Conference: Geneva, Switzerland; April 2008
145. IMPAIRMENT OF THE DNA REPAIR AND GROWTH ARREST PATHWAYS BY p53R2 SILENCING ENHANCES DNA DAMAGE- INDUCED APOPTOSIS IN A p53-DEPENDENT MANNER IN PROSTATE CANCER CELLS: 1235
146. TARGETING SRC AND MULTIPLE RECEPTOR TYROSINE KINASES (RTKs) SIMULTANEOUSLY RESULTED IN SYNERGISTIC INHIBITION OF PROLIFERATION AND SUPERIOR REDUCTION OF MIGRATION OF RENAL CANCER CELLS: 97
147. Pharmacogenomic Approaches to Individualizing Chemotherapy for Non-Small-Cell Lung Cancer: Current Status and New Directions
148. Brief Report: SWOG S1400D (), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
149. GCP-Mediated Growth Inhibition and Apoptosis of Prostate Cancer Cells Via Androgen Receptor-Dependent and -Independent Mechanisms
150. Epidermal Growth Factor Receptor Inhibitors plus Chemotherapy in Non-Small-Cell Lung Cancer: Biologic Rationale for Combination Strategies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.